RGNX

REGENXBIO is a clinical-stage biotechnology company developing gene therapies using its proprietary adeno-associated virus (AAV) platform. The company advances treatments for genetic diseases affecting the eye, liver, and central nervous system. REGENXBIO also licenses its NAV Technology Platform to other biotech and pharmaceutical companies, creating a dual revenue model from internal development and technology partnerships.